Eledon Pharmaceuticals, Inc. (ELDN) Stock Forecast
ELDN analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 6 analysts
- Price target
- $9.00 average of analyst targets
- Upside to target
- +322.5% from the latest close
- Next earnings
- November 13, 2026 EPS estimate $-0.20
- 52-week range
- $1.39 – $4.36
ELDN analyst ratings
6 analystsNumber of analysts at each rating.
ELDN price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ELDN earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.19 | −$0.21 | −$0.15 | −$0.21 | +9.5% | 4 |
| Current fiscal year (2026) | −$0.93 | −$1.04 | −$0.77 | −$0.52 | −79.3% | 4 |
| Next fiscal year (2027) | −$0.77 | −$0.92 | −$0.67 | −$0.93 | +17.4% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ELDN revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 5 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 5 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 4 |
ELDN EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ELDN EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.18 | −$0.18 | −$0.19 | −$0.19 | −$0.19 | +2.7% | 1 up · 2 down |
| Current fiscal year (2026) | −$0.87 | −$0.87 | −$0.93 | −$0.93 | −$0.93 | +6.9% | 0 up · 2 down |
| Next fiscal year (2027) | −$0.72 | −$0.72 | −$0.77 | −$0.77 | −$0.77 | +6.5% | 1 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ELDN earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ELDN beat in 7 of 12.
What analysts expect from ELDN
6 analysts cover Eledon Pharmaceuticals; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $9.00, 322.5% above the latest close of $2.13. Analysts expect earnings of −$0.93 per share for 2026, −79.3% from a year earlier. For 2027 the average estimate is −$0.77 per share. Eledon Pharmaceuticals beat the EPS estimate in 7 of the last 12 quarters.
Related: ELDN income statement, ELDN key metrics, ELDN chart. See the ELDN stock overview for the latest quote and news.
ELDN forecast FAQ
What is Eledon Pharmaceuticals's price target?
The average analyst price target for Eledon Pharmaceuticals is $9.00, 322.5% above the latest close of $2.13.
Is Eledon Pharmaceuticals a buy, hold or sell?
Of 6 analysts covering Eledon Pharmaceuticals, 6 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Eledon Pharmaceuticals's EPS forecast?
Analysts forecast −$0.93 per share for 2026 (range −$1.04 to −$0.77); for 2027 the estimate is −$0.77.
When does Eledon Pharmaceuticals report earnings?
Eledon Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 13, 2026 after the market closes; the EPS estimate is $-0.20.
Does Eledon Pharmaceuticals usually beat earnings estimates?
Eledon Pharmaceuticals reported EPS at or above the analyst estimate in 7 of the last 12 quarters.